CBPO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CBPO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
China Biologic Products Holdings's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2020 was $56.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2020 was $198.6 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China Biologic Products Holdings's annualized ROC % for the quarter that ended in Sep. 2020 was 19.43%. China Biologic Products Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was 52.45%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. China Biologic Products Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was 5.46%.
The historical data trend for China Biologic Products Holdings's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biologic Products Holdings Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
EBIT | Get a 7-Day Free Trial | 136.83 | 154.17 | 146.99 | 166.34 | 192.05 |
China Biologic Products Holdings Quarterly Data | ||||||||||||||||||||
Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | |
EBIT | Get a 7-Day Free Trial | 61.29 | 21.23 | 73.96 | 47.23 | 56.21 |
For the Biotechnology subindustry, China Biologic Products Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where China Biologic Products Holdings's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $198.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biologic Products Holdings (NAS:CBPO) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
China Biologic Products Holdings's annualized ROC % for the quarter that ended in Sep. 2020 is calculated as:
ROC % (Q: Sep. 2020 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Jun. 2020 ) | + | Invested Capital (Q: Sep. 2020 )) | / count ) |
= | 208.064 * ( 1 - 17.29% ) | / | ( (859.553 | + | 911.718) | / 2 ) |
= | 172.0897344 | / | 885.6355 | |||
= | 19.43 % |
where
Invested Capital | (Q: Jun. 2020 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 2024.424 | - | 123.901 | - | ( 1040.97 | - | max(0, 123.901 | - | 1402.519 | + | 1040.97 | )) |
= | 859.553 |
Invested Capital | (Q: Sep. 2020 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 2139.513 | - | 124.449 | - | ( 1103.346 | - | max(0, 124.449 | - | 1494.958 | + | 1103.346 | )) |
= | 911.718 |
Note: The Operating Income data used here is four times the quarterly (Sep. 2020) data.
2. Joel Greenblatt's definition of Return on Capital:
China Biologic Products Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:
ROC (Joel Greenblatt) % | (Q: Sep. 2020 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Jun. 2020 | Q: Sep. 2020 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | 224.832 | / | ( ( (172.369 + max(237.648, 0)) | + | (180.065 + max(267.163, 0)) ) | / | 2 ) |
= | 224.832 | / | ( ( 410.017 | + | 447.228 ) | / | 2 ) |
= | 224.832 | / | 428.6225 | ||||
= | 52.45 % |
where Working Capital is:
Working Capital | (Q: Jun. 2020 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (114.636 | + | 225.578 | + | 21.335) | - | (123.901 | + | 0 | + | 0) |
= | 237.648 |
Working Capital | (Q: Sep. 2020 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (136.133 | + | 234.465 | + | 21.014) | - | (124.449 | + | 0 | + | 0) |
= | 267.163 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
China Biologic Products Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Sep. 2020 ) |
= | 198.627 | / | 3640.333 | |
= | 5.46 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of China Biologic Products Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhijing Cbpo Liu | officer: Corporate Vice President | 19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125 |
Sean Shao | director | 21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040 |
David Gao | director, officer: Chief Executive Officer | C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Albert Yeung | director | C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
David Hui Li | director | C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 |
Min Fang | director | UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002 |
Zhijun Tong | director | C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Joseph Chow | director | 10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121 |
Yungang Lu | director | 4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086 |
Warburg Pincus Llc | 10 percent owner | 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Wp X Biologics Llc | director, 10 percent owner | C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017 |
Warburg Pincus X Partners, L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Warburg Pincus Private Equity X, L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Warburg Pincus X Gp L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Warburg Pincus X, L.p. | director, 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
From GuruFocus
By Tiziano Frateschi Tiziano Frateschi • 08-29-2019
By PRNewswire PRNewswire • 03-01-2021
By GuruFocus Research GuruFocus Editor • 05-14-2021
By [email protected] insider • 02-17-2020
By PRNewswire PRNewswire • 10-17-2019
By PRNewswire PRNewswire • 01-25-2021
By [email protected] insider • 06-05-2020
By PRNewswire PRNewswire • 11-19-2020
By PRNewswire PRNewswire • 08-10-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.